Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Patient enrollment completed for phase I/II pancreatic cancer trial

March 13, 1998

Avicidin advances to phase II

March 5, 1998

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

March 4, 1998

Phase I/II trial results reported for OncoVax-P formulated with JenVax-100a

March 3, 1998

IDEC-Y2B8/rituximab combination enters phase III

Feb. 27, 1998

UCSF receives green light to develop new breast cancer therapy

Feb. 24, 1998

Maxamine progresses to phase III in AML

Feb. 23, 1998

Phase I trial results of DAB389IL-2 in lymphoma

Feb. 20, 1998

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...